Bank of New York Mellon’s Ovid Therapeutics OVID Stock Holding History

Bank of New York Mellon’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Buy	416,318 +361,280	+656%	+$932K	﹤0.01%	3295
2026 Q1	$122K	Sell	55,038 -2,660	-5%	-$4.76K	﹤0.01%	4080
2025 Q4	$94K	Hold	57,698	–	–	﹤0.01%	4108
2025 Q3	$75K	Buy	57,698 +1	+0%	+$1	﹤0.01%	4112
2025 Q2	$19K	Sell	57,697 -108,066	-65%	-$32.6K	﹤0.01%	4115
2025 Q1	$51.7K	Hold	165,763	–	–	﹤0.01%	4052
2024 Q4	$155K	Hold	165,763	–	–	﹤0.01%	3992
2024 Q3	$196K	Sell	165,763 -52,400	-24%	-$54.7K	﹤0.01%	3913
2024 Q2	$168K	Sell	218,163 -11,390	-5%	-$31.7K	﹤0.01%	3977
2024 Q1	$700K	Sell	229,553 -19,256	-8%	-$64.4K	﹤0.01%	3334
2023 Q4	$801K	Sell	248,809 -1,271	-0.5%	-$4.34K	﹤0.01%	3309
2023 Q3	$960K	Buy	250,080 +442	+0.2%	+$1.59K	﹤0.01%	3181
2023 Q2	$819K	Buy	249,638 +166,624	+201%	+$566K	﹤0.01%	3325
2023 Q1	$214K	Hold	83,014	–	–	﹤0.01%	3890
2022 Q4	$154K	Sell	83,014 -140,474	-63%	-$239K	﹤0.01%	4044
2022 Q3	$411K	Buy	223,488 +4,601	+2%	+$9.63K	﹤0.01%	3679
2022 Q2	$470K	Sell	218,887 -12,121	-5%	-$29.3K	﹤0.01%	3641
2022 Q1	$726K	Sell	231,008 -21,165	-8%	-$66.6K	﹤0.01%	3499
2021 Q4	$810K	Buy	252,173 +134,673	+115%	+$461K	﹤0.01%	3506
2021 Q3	$396K	Buy	117,500 +25,653	+28%	+$93.5K	﹤0.01%	3928
2021 Q2	$359K	Sell	91,847 -59,183	-39%	-$234K	﹤0.01%	3912
2021 Q1	$607K	Buy	151,030 +15,767	+12%	+$52.4K	﹤0.01%	3579
2020 Q4	$313K	Buy	135,263 +13,708	+11%	+$63.9K	﹤0.01%	3809
2020 Q3	$698K	Sell	121,555 -1,018	-0.8%	-$6.81K	﹤0.01%	3323
2020 Q2	$903K	Buy	122,573 +101,110	+471%	+$473K	﹤0.01%	3165
2020 Q1	$64K	Buy	+21,463	New	+$72.3K	﹤0.01%	3932
2019 Q2	–	Sell	-34,650	Closed	-$61K	–	4263
2019 Q1	$61K	Sell	34,650 -116	-0.3%	-$290	﹤0.01%	4075
2018 Q4	$84K	Buy	34,766 +35	+0.1%	+$160	﹤0.01%	3987
2018 Q3	$197K	Buy	34,731 +3,036	+10%	+$23K	﹤0.01%	3937
2018 Q2	$247K	Buy	31,695 +6,307	+25%	+$54.1K	﹤0.01%	3876
2018 Q1	$180K	Buy	25,388 +11,889	+88%	+$96.2K	﹤0.01%	3951
2017 Q4	$133K	Buy	13,499 +661	+5%	+$6.07K	﹤0.01%	4026
2017 Q3	$110K	Sell	12,838 -32	-0.2%	-$266	﹤0.01%	3996
2017 Q2	$135K	Buy	+12,870	New	+$168K	﹤0.01%	3973

Other funds holding OVID

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SIM

Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

SFG

Sovereign Financial Group Stamford, Connecticut $654M AUM 32.34% 1-Year Est. Return

Bank of New York Mellon's OVID Position: Q2 2026 in Review

Bank of New York Mellon increased its Ovid Therapeutics (OVID) stake by 656% in Q2 2026, buying an estimated $932K and bringing the position to 416,318 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3295.

Bank of New York Mellon first reported a position in OVID in Q2 2017 and has held it in 34 quarters since. 35 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Bank of New York Mellon held 416,318 shares of Ovid Therapeutics worth $1.12M as of Q2 2026.
Bank of New York Mellon bought 361,280 Ovid Therapeutics shares in Q2 2026, an estimated $932K.
Ovid Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3295 holding.
Bank of New York Mellon first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 34 quarters since.
35 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.